Literature DB >> 3882119

Hepatic necrosis and glutathione depletion in captopril-treated mice.

T R Helliwell, J H Yeung, B K Park.   

Abstract

Captopril (CP) is an angiotensin-converting enzyme inhibitor whose metabolism involves endogenous thiols which may be depleted at high doses of CP. Following intraperitoneal administration of CP (50-300 mg/kg), dose-dependent depletion of hepatic glutathione, increased serum transaminase (SGPT) levels and hepatic necrosis were observed. The hepatic necrosis observed was either subcapsular or parenchymal in distribution. Both types of necrosis showed a dose-dependent increase in severity but with a large inter-animal variation. The patterns of necrosis observed with CP are different from the necrosis caused by paracetamol. Oral CP (300 mg/kg) caused parenchymal necrosis in only one animal. It is suggested that subcapsular necrosis may be due to the direct effect of i.p. captopril whereas parenchymal necrosis may be a consequence of hepatic GSH depletion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3882119      PMCID: PMC2041016     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  17 in total

Review 1.  Captopril in the treatment of clinical hypertension and cardiac failure.

Authors:  A B Atkinson; J I Robertson
Journal:  Lancet       Date:  1979-10-20       Impact factor: 79.321

2.  Temporary ageusia related to captopril.

Authors:  P H Vlasses; R K Ferguson
Journal:  Lancet       Date:  1979-09-08       Impact factor: 79.321

3.  Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite.

Authors:  D J Jollow; J R Mitchell; N Zampaglione; J R Gillette
Journal:  Pharmacology       Date:  1974       Impact factor: 2.547

4.  Disposition of captopril in normal subjects.

Authors:  K J Kripalani; D N McKinstry; S M Singhvi; D A Willard; R A Vukovich; B H Migdalof
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

5.  The distribution of glutathione in the rat liver lobule.

Authors:  M T Smith; N Loveridge; E D Wills; J Chayen
Journal:  Biochem J       Date:  1979-07-15       Impact factor: 3.857

6.  Angiotensin converting enzyme inhibition in patients with congestive heart failure.

Authors:  H Gavras; D P Faxon; J Berkoben; H R Brunner; T J Ryan
Journal:  Circulation       Date:  1978-11       Impact factor: 29.690

7.  Drug protein conjugates--VI. Role of glutathione in the metabolism of captopril and captopril plasma protein conjugates.

Authors:  J H Yeung; A M Breckenridge; B K Park
Journal:  Biochem Pharmacol       Date:  1983-12-01       Impact factor: 5.858

8.  Lipid peroxidation as a consequence of glutathione depletion in rat and mouse liver.

Authors:  M Younes; C P Siegers
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1980-01

9.  Acute hepatitis B associated with gynaecological surgery.

Authors: 
Journal:  Lancet       Date:  1980-01-05       Impact factor: 79.321

10.  Proteinuria during long-term captopril therapy.

Authors:  D B Case; S A Atlas; J A Mouradian; R A Fishman; R L Sherman; J H Laragh
Journal:  JAMA       Date:  1980-07-25       Impact factor: 56.272

View more
  1 in total

1.  Prediction of clinically relevant safety signals of nephrotoxicity through plasma metabolite profiling.

Authors:  W B Mattes; H G Kamp; E Fabian; M Herold; G Krennrich; R Looser; W Mellert; A Prokoudine; V Strauss; B van Ravenzwaay; T Walk; H Naraoka; K Omura; I Schuppe-Koistinen; S Nadanaciva; E D Bush; N Moeller; P Ruiz-Noppinger; S P Piccoli
Journal:  Biomed Res Int       Date:  2013-05-21       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.